Science and The Lancet Publish Results Using Illumina's HumanHap300 BeadChip
Tuesday December 5, 6:00 am ET
Studies Report Findings in Crohn's Disease and Parkinson's Disease
SAN DIEGO--(BUSINESS WIRE)--Illumina (NASDAQ:ILMN - News) today announced that important results from genotyping research in Crohn's disease and Parkinson's disease (PD) using Illumina's Infinium® HumanHap300 BeadChip were published in peer-reviewed journals, Science and The Lancet.
Using the HumanHap300 BeadChip, a consortium of United States and Canadian researchers uncovered a breakthrough discovery in Inflammatory Bowel Disease (IBD). The study's authors, who represent the National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) IBD Genetics Consortium, found that variants in a gene that codes for part of the immune cell receptor for interleukin-23 (IL-23R) are strongly associated with Crohn's disease and ulcerative colitis, collectively called IBD. Findings from this study appeared in the December 1 issue of Science, and will be discussed during an Illumina-sponsored Webinar with lead authors on Monday, January 15, 2007. To register for this event, please visit www.illumina.com/infinium/webinars.
Under the direction of Peter Gregersen, M.D., and Annette Lee, Ph.D., genotyping for the IBD study was conducted on Illumina's genetic analysis system at The Robert S. Boas Center for Genomics and Human Genetics at the Feinstein Institute for Medical Research, North Shore-Long Island Jewish Health System.
Senior author Judy H. Cho, M.D., Associate Professor of Medicine and Genetics at Yale School of Medicine said, "Our team chose to work with Illumina's HumanHap300 BeadChip because it provided outstanding quality and genomic coverage necessary to efficiently and effectively identify the genetic basis behind IBD." First author of the study, Richard H. Duerr, M.D., Associate Professor of Medicine and Human Genetics at the University of Pittsburgh added, "More importantly, due to the speed and accuracy of the technology and the significance of the results, only 10 months elapsed between initiating the study and publication."
A second study published in the September 27 online issue of The Lancet also employed the HumanHap300 BeadChip, which completed one of the first large-scale studies of genetic variation in PD. Led by Andrew Singleton, Ph.D., of the National Institute of Aging (NIA), results from the study will help to pave the way towards continued research in PD and other neurological diseases.
"In less than a year after the International HapMap Project's conclusion, and within eight months of the HumanHap300 BeadChip launch, the new discoveries in Crohn's and Parkinson's disease signify the power of the Infinium whole-genome association technology to uncover the genetic basis of complex diseases," said Jay Flatley, Illumina President and Chief Executive Officer. "We believe Illumina's BeadChips set the gold standard in the industry for performance, quality and coverage."
About the HumanHap300 BeadChip
Illumina's HumanHap300 BeadChip enables whole-genome genotyping of over 317,000 tagSNP markers derived from the International HapMap Project (www.hapmap.org). The BeadChip is powered by the Infinium Assay which enables intelligent SNP selection utilizing tagSNPs. The HumanHap300 is also available in a two-sample BeadChip (HumanHap300-Duo), or can be customized with up to 60,800 additional custom SNPs (HumanHap300-Duo+). For more information about Infinium technology, please visit www.illumina.com/infinium. |
